SMMT · Summit Therapeutics Inc.
$13.35
-0.65 (-4.64%)
At close · Aug 14
Market Cap
$10.65B
Shares
797.75M
Summit Therapeutics Inc. Earnings Call Transcripts
Every quarterly earnings call for Summit Therapeutics Inc. (SMMT) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
Earnings call
FY26 · Q2
2026-07-23
Summit Therapeutics Q2 2026 Earnings Call
Confident tone
HARMONY trial updated OS analysis
HARMONY 3 and HARMONY 6 NSCLC trials
Commercial uptake in China
Diluted EPS
$-0.28
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-08
Summit Therapeutics Presents at Goldman Sachs Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-06-01
Summit Therapeutics Inc. Q1 FY2026 Earnings Call
Diluted EPS
$-0.24
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-23
Summit Therapeutics Inc. Q4 FY2025 Earnings Call
Confident tone
Ivonescimab data readouts and approvals
FDA BLA review and HARMONi regulatory path
HARMONi-3 trial progress and interim analysis
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-10-20
Summit Therapeutics Inc. Q3 FY2025 Earnings Call
Confident tone
BLA submission for ivonescimab
HARMONi-6 Phase III data in squamous NSCLC
HARMONi-3 independent histologies and filing strategy
Diluted EPS
$-0.31
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-01
Summit Therapeutics Inc. Q1 FY2025 Earnings Call
Confident tone
HARMONi global Phase III trial readout
Ivonescimab clinical progress and regulatory milestones
Partnership with Akeso
Diluted EPS
$-0.09
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-24
Summit Therapeutics Inc. Q4 FY2024 Earnings Call
Confident tone
Harmony 3 amendment and patient population expansion
Pfizer ADC collaboration
Harmony 7 monotherapy vs pembrolizumab trial
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-30
Summit Therapeutics Inc. Q3 FY2024 Earnings Call
Confident tone
HARMONi-3 amendment to include non-squamous NSCLC
HARMONi EGFR-mutant Phase 3 enrollment and timeline
HARMONi-2 ivonescimab vs pembro data
Revenue
$
Diluted EPS
$-0.08
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
Summit Therapeutics Inc. Q2 FY2024 Earnings Call
Diluted EPS
$-0.09
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-01
Summit Therapeutics Inc. Q1 FY2024 Earnings Call
Confident tone
Ivonescimab clinical development and mechanism
HARMONi and HARMONi-3 registrational trials
Akeso partnership and HARMONi-A data
Diluted EPS
$-0.06
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-20
Summit Therapeutics Inc. Q4 FY2023 Earnings Call
Confident tone
Ivonescimab lead asset progress
Unmet need in lung cancer
Akeso partnership and global trials
Revenue
$*
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Summit Therapeutics Inc. Q3 FY2023 Earnings Call
Revenue
$
▼ 100% YoY Diluted EPS
$-0.03
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-09
Summit Therapeutics Inc. Q2 FY2023 Earnings Call
Revenue
$
▼ 100% YoY Diluted EPS
$-0.02
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-11
Summit Therapeutics Inc. Q1 FY2023 Earnings Call
Revenue
$
▼ 100% YoY Diluted EPS
$-1.43
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-09
Summit Therapeutics Inc. Q4 FY2022 Earnings Call
Revenue
$*
▼ 100% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–15 of 15 earnings calls
Key facts
CIK
1599298
CUSIP
86627T108
13F (30d)
233 filings
231 filers
Visit website
Investor relations